The Value of Drug Repositioning: Longer Patent Life
According to Gene Logic, there's value in failed Phase II candidates-so long as safety's not the problem. The company claims that repositioning a compound in a new indication creates an asset worth 27% more, in net present value terms, than an equivalent in-licensed drug.
You may also be interested in...
Israel's Obecure is investigating the potential of a marketed compound, betahistine, in obesity. It's hoping this repositioning approach will both accelerate timelines and help it overcome growing drug safety hurdles.
The Heyday of Biotech Dealmaking
Deal values and perks are up for biotechs; the Pharmaceutical Strategic Outlook conference suggests Big Pharma might begin to borrow some biotech strategies.
A New Approach to Repurposing: Ditch the Hypotheses
By pulling together 35 publicly available gold-standard animal models, Melior Discovery has built a stable of what it calls privileged compounds. The repurposing company augments its VC funds with service deals and is aiming to progress its lead compound into Phase I studies in 2007.